More potent and less toxic formulations of epinephrine and methods of medical use
The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine, including preventing and or treating hypotension and hemostasis under surgical anesthesia.
1. A method of treating a patient having, developing, or recovering from septic shock with a continuous intravenous infusion of l-epinephrine delivered via an at least one intravenous fluid bag with an at least one intravenous line and/or an at least one intravenous catheter, said at least one intravenous fluid bag containing up to 1,000 mL of a saline solution or a dextrose and sodium chloride-containing solution, said method comprising:
a) injecting an at least a portion of an at least one greater than 2 mL prefilled container of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine into each said at least one intravenous fluid bag or medication port thereof, so that the at least one intravenous fluid bag has a diluted concentration of l-epinephrine of about 1 microgram per mL, wherein said at least one greater than 2 mL prefilled container injectable liquid pharmaceutical formulation of l-epinephrine comprises a tonicity agent and is free of epinephrine bitartrate ingredient;
b) said method further comprising administering said continuous intravenous infusion of l-epinephrine to said patient at said diluted concentration of l-epinephrine at about 1 microgram per mL;
c) said method further comprising titrating said continuous infusion of l-epinephrine based on a blood pressure of said patient to achieve the desired hemodynamic goals or to stabilize said patient's vital signs;
d) said method further comprising weaning said continuous infusion of l-epinephrine;
e) said method optionally comprising protecting said at least one said intravenous fluid bag from light or UV-radiation after said step of injecting said at least a portion of said at least one greater than 2 mL prefilled container into said at least one intravenous fluid bag or medication port thereof to prevent l-epinephrine degradation and impurities from forming so that said continuous intravenous infusion of l-epinephrine has a ratio of l-epinephrine:d-epinephrine greater than 4:1.
2. The method of claim 1 , wherein the method results in increasing heart rate and heart contractility in the patient.
3. The method of claim 1 , wherein the at least one intravenous fluid bag is at least two intravenous fluid bags.
4. The method of claim 1 , wherein the step (b) is administered for at least half a day.
5. The method of claim 1 , wherein the step (b) is administered for at least one day.
6. The method of claim 1 , wherein each at least one greater than 2 mL prefilled container injectable liquid pharmaceutical formulation of l-epinephrine has no more than 12.5% total impurities or no more than 12% d-epinephrine.
7. The method of claim 1 , wherein the at least one greater than 2 mL prefilled container of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine is at least two greater than 2 mL prefilled container vials or bottles of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine.
8. The method of claim 1 , wherein the at least one greater than 2 mL prefilled container of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine is a vial or bottle that contains at least 2.5 mL of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine.
9. The method of claim 1 , wherein the at least one greater than 2 mL prefilled container of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine is a vial or bottle that contains at least 10 mL of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine.
10. The method of claim 1 , wherein the at least one greater than 2 mL prefilled container of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine is a vial or bottle that contains at least 30 mL of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine.
11. The method of claim 1 , wherein the at least one greater than 2 mL prefilled container of a 1 mg per mL injectable liquid pharmaceutical formulation of l-epinephrine is a vial or bottle that contains multiple doses of l-epinephrine to prepare multiple intravenous fluid bags with a diluted concentration of l-epinephrine of about 1 microgram per mL in each intravenous fluid bag.